Pentagon Rolls Out — Then Pauses — Mandatory Troop Testosterone Screening
The Pentagon issued mandatory testosterone screening guidance for troops 30 and older, then temporarily rescinded the memo a day later. Doctors are skeptical, and an FDA meeting on testosterone looms.
The Pentagon issued clinical guidance on Wednesday mandating testosterone deficiency screening for active-duty and reserve service members age 30 and older, then pulled the memo roughly a day later, per Reuters.
The move follows Defense Secretary Pete Hegseth’s July announcement of the program and is drawing scrutiny from medical experts over the science behind it.
What the guidance said
The Pentagon issued detailed guidance on Wednesday for a new, mandatory testosterone deficiency screening policy for active-duty and reserve service members age 30 and older, effective immediately, establishing standardized screening and treatment pathways for men and women aimed at improving military readiness by identifying and managing hormonal and energy-availability issues.
Men aged 30 and older would be screened through a questionnaire that could then trigger a blood test for testosterone levels and, if needed, testosterone hormone therapy. Women would also be screened through a questionnaire, which could then move to treatment for conditions related to hormonal imbalance.
Then the reversal
The Pentagon is temporarily rescinding the recently published clinical guidance for the mandatory testosterone-deficiency screening policy, a U.S. official told Reuters on Thursday.
On Wednesday, the Pentagon posted the “Clinical Guidance for Health and Human Performance Optimization” on its website. By Thursday, the memo and an accompanying statement from spokesperson Sean Parnell had been removed. The draft published on September 2, 2026, has been temporarily rescinded to allow for updates, the official said, adding that interim guidance remains in effect.
Do you want to see how to make more plays? Do you want to find gains yourself?
Unusual Whales helps you find market opportunities through our market tide, historical options flow, GEX, and much, much more.
Create a free account here to start conquering the market with Unusual Whales.
Why doctors are pushing back
Doctors have raised concerns that broad testosterone testing could lead to unnecessary, or potentially harmful, treatment, saying there is little evidence that universal screening for low testosterone among military personnel would improve U.S. combat readiness.
The U.S. Food and Drug Administration plans to hold a meeting of experts to discuss the medical use of testosterone in mid-September. That FDA meeting could set the tone for how quickly any revised Pentagon guidance actually rolls out.
Options market and stocks to watch
Even a paused policy would represent a meaningful demand signal for testosterone replacement therapy and adjacent hormone products. A few tickers worth watching:
- ABBV — AbbVie markets AndroGel, one of the most widely prescribed testosterone therapies. Watch for flow if Pentagon volumes get quantified.
- LLY — Eli Lilly markets Axiron and has broader hormone therapy exposure. Watch for reaction into the FDA meeting.
- HIMS — Hims & Hers has leaned into men’s health and TRT-adjacent offerings; broader public attention on testosterone could pull through to consumer demand.
- HLF and other supplement-adjacent names — watch for retail chatter tied to “low T” headlines.
For related coverage and flow context, see more Unusual Whales news.
Want more market intelligence? Create your free Unusual Whales account for options flow, market tide, GEX, and the full toolkit.